Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
about
Resistant mechanisms to BRAF inhibitors in melanomaCIViC databaseEZH2 as a mediator of treatment resistance in melanomaMAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived XenograftsCombining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seqMolecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patientsZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance.Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma modelMapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq.Precision medicine driven by cancer systems biology.microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response.Monitoring immune responses in the tumor microenvironment.Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation.Cancer Immunotherapy, Part 3: Challenges and Future Trends.Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma.Immunotherapy for advanced melanoma: future directions.Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies.Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.Tumour heterogeneity: principles and practical consequences.Targeted agents and immunotherapies: optimizing outcomes in melanoma.Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.High-throughput genomic profiling of tumor-infiltrating leukocytes.Metastatic melanoma moves on: translational science in the era of personalized medicine.Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.The Senescence-Associated Secretory Phenotype: Critical Effector in Skin Cancer and Aging.Intralesional and systemic immunotherapy for metastatic melanoma.Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.Gene-expression profiling to predict responsiveness to immunotherapy.Mechanisms of Drug Resistance in Melanoma.Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
P2860
Q26739717-98CFFBAB-7BA1-4003-9EDC-803A3E210D1EQ27612411-67E1DFDA-3B9C-459B-B494-762488A22E3DQ28074492-78B1ACB1-3A0A-4A35-B87F-C04A8D2D3048Q33566681-E3E406EB-F7FB-4194-ADBD-9585700DF416Q36730827-C8C8977F-1C06-4693-8CD8-1B8C7520C0ECQ36759354-0AEEAA2A-E264-4D4B-96ED-59403AC01000Q37056708-237895E9-B6A9-4B63-B173-A484775A6E71Q37066925-9C120350-AFB8-4F88-B467-CC2DC609BCF2Q37094024-5F869F77-A3C7-4700-974E-22B223602349Q37148418-9AB11B17-BF1D-4461-8B25-EF82D0ECF16CQ37307458-CA04CE43-7357-4A56-A3CD-75D880667B87Q37407636-3A861926-3AD5-4EED-8664-662B8F0A2679Q37417271-DB64221F-E26D-4766-BE7A-34AC2DBEE418Q37595877-9B811749-9281-450F-A967-F2C6AD30068DQ37689031-4753B06A-5DE3-4E8E-AD7D-E8F5A5983114Q37702372-4BC2DD87-53B9-4AF2-8392-D7D2062ED7D3Q37742635-776B63B4-E3DC-4260-9E78-B09C753CC82CQ38376771-94908D2E-CBE2-48A4-BA73-3D3998D4F0B0Q38380080-5CDEBF3B-1CD8-4085-9B6B-86C56EBA201CQ38618945-D479601B-BD7E-4225-A5E7-AD13C2146B1AQ38622789-1A796D6B-F961-48CC-8721-2359298F2656Q38646290-9FE498E3-A875-4D77-BC7C-7DC23568C773Q38691932-D9837DE5-D06C-4328-807D-0826441F5C9AQ38711163-1840D85F-0A64-4B02-8A56-74136787355CQ38716324-BF4594E9-F276-48C8-A5AE-E5F5D043244CQ38753142-1219A464-0BE6-4389-97EB-ADE69DBCEB61Q38756275-3A33E1A6-B25D-4B0A-B8A0-EA7771489774Q38813507-79F6D607-B8E2-4AC4-A8C7-5C827514285AQ38842168-7D53219F-A225-4FB1-A712-4EE1579D812BQ38856722-ACBD7884-122C-4773-88C1-E054B545BE86Q38874383-42AE0068-4592-461B-AF20-D4E46B3CF116Q38884388-5B489C10-39A2-4FC1-ADC8-BAA598A82846Q38891959-976349E0-4BFB-411C-B132-DA1DCC9AAAE3Q38917480-898F372E-5B84-4EEF-A25C-89039B44AB04Q38932691-FCA83A5E-8292-4EA4-8689-BE07168EF5DCQ38948218-8CDB8E01-7CBD-4DF1-ADA2-367A4A92CD67Q38950577-8382FA91-5E39-4A60-B69E-4C98CF58F663Q39005203-7A100C5A-0F0C-4368-B664-D3FCD144A67DQ39169776-74AD88CB-D29A-4878-98C9-D423061F70A6Q39195305-913A0105-9C6A-4AA8-B916-01400FC64193
P2860
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
@ast
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
@en
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
@nl
type
label
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
@ast
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
@en
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
@nl
altLabel
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
@en
prefLabel
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
@ast
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
@en
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
@nl
P2093
P2860
P4510
P50
P3181
P1433
P1476
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
@en
P2093
Aayoung Hong
Antoni Ribas
Chunying Song
Douglas B Johnson
Gatien Moriceau
Jeffrey A Sosman
Kimberly B Dahlman
Roger S Lo
Xiangju Kong
P2860
P304
P3181
P356
10.1016/J.CELL.2015.07.061
P407
P577
2015-09-10T00:00:00Z